Published On: Fri, Aug 20th, 2021
World | By

AstraZeneca Antibody Cocktail 77 Percent Effective Against Symptomatic COVID-19 in Trialon August 20, 2021 at 2:24 pm

Share This

AstraZeneca said Friday it plans to apply for regulatory approval of an antibody cocktail that a preliminary study showed was highly effective in preventing symptomatic COVID-19, offering a potential alternative or complement to vaccines. The Anglo-Swedish drugmaker announced in an Aug. 20 release that the drug, a combination of two long-acting antibodies derived from convalescent plasma, reduced the risk of symptomatic COVID-19 by 77 percent in a clinical trial. The antibody cocktail, called AZD7442, was evaluated in a randomized, double-blind, placebo-controlled trial involving over 5,000 across multiple countries, including the United States. While the study has not yet been peer-reviewed, AstraZeneca said full results would be submitted for publication in a peer-reviewed medical journal. None of the trial participants who received AstraZeneca’s drug, administered as a single shot via intramuscular injection, developed severe COVID-19 or died from the disease, according to the release. There were three cases of severe illness and two … Save 10% on Citrus trees with code CITRUS

About the Author